Search

Your search keyword '"van Asperen CJ"' showing total 298 results

Search Constraints

Start Over You searched for: Author "van Asperen CJ" Remove constraint Author: "van Asperen CJ"
298 results on '"van Asperen CJ"'

Search Results

1. Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats

2. Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non‐high‐grade serous ovarian carcinomas

3. Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non‐high‐grade serous ovarian carcinomas.

4. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

5. Uncovering the Contribution of Moderate-Penetrance Susceptibility Genes to Breast Cancer by Whole-Exome Sequencing and Targeted Enrichment Sequencing of Candidate Genes in Women of European Ancestry.

6. Breast cancer risks associated with missense variants in breast cancer susceptibility genes

7. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

8. Long-term morbidity and health after early menopause due to oophorectomy in women at increased risk of ovarian cancer: Protocol for a nationwide cross-sectional study with prospective follow-up (HARMOny Study)

9. Reproductive decision-making in the context of hereditary cancer: the effects of an online decision aid on informed decision-making

10. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations

12. Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

13. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

14. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

15. Transcriptome-wide association study of breast cancer risk by estrogen-receptor status

16. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

17. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

18. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification

19. Genome-wide association study of germline variants and breast cancer-specific mortality

20. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers

21. Online decision support for persons having a genetic predisposition to cancer and their partners during reproductive decision-making

22. The development of an online decision aid to support persons having a genetic predisposition to cancer and their partners during reproductive decision-making: a usability and pilot study

23. An alternative approach to establishing unbiased colorectal cancer risk estimation in Lynch syndrome.

24. The BRCA2 c.68‐7T > A variant is not pathogenic:a model for clinical calibration of spliceogenicity

25. EP973 ‘Tumour First’: an institutional experience of reflex tumour BRCA testing in ovarian epithelial carcinomas

26. The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity

27. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

28. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

29. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

30. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

31. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (vol 118, pg 266, 2018)

32. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

33. Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue

34. Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers

35. E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium

36. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

37. Performance of BRCA1/2 mutation prediction models in male breast cancer patients

38. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

39. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

40. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients

41. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

42. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

43. The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers

44. Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study

45. Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1

46. FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor

47. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

48. MicroRNA Related Polymorphisms and Breast Cancer Risk

49. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation

50. MicroRNA Related Polymorphisms and Breast Cancer Risk

Catalog

Books, media, physical & digital resources